Degron Therapeutics aims to become a global leader in the discovery and development of a new class of targeted protein degradation therapeutics, small molecule molecular glue degrader (MGD) drugs. Degron has assembled a team of world-class executives and scientific leaders, bringing its scientific excellence to the identification and validation of disease targets, particularly those undruggable by conventional small molecule inhibitors, and novel selective MGD compounds to meet unmet medical needs in all therapeutic areas.
Molecular glue protein degradation platform to discover novel drugs
About 80% of disease targets are "undruggable" by existing technologies
Innovative molecular glue degraders to drug the "undruggable" targets and bring a new class of treatment for various diseases
2021
2021
Founded in 2021
Professional and Dedicated
$34.5M
$34.5M
Raised from blue chip venture capital investors
20+
20+
Molecular glue discovery platform accelerating a broad pipeline of more than 20 projects
40+
40+
In vitro and in vivo target discovery and validation techniques
deep scientific knowledge
Founded on the IP and knowhow by Professor Yong Cang at ShanghaiTech University, from over 20 years of Cereblon ubiquitin ligase research.
WIN-WIN COLLABORATION
Co-founder Professor Cang's ShanghaiTech University laboratory has formed a partnership with MNC pharma.
PROPRIETARY AND UNIQUE GLUE LIBRARY
Degron's library started from a novel chemical scaffold that is patented by founder's lab. Degron has expanded the diversity (about 60+ diverse cores) and number of compounds (6000+) in the library, which continues to grow at 160 new compounds per week.
MULTIPLE SCREENING PLATFORMS
Degron uses three different but complementary strategies. In addition to target-based compound screen approach that most MGD companies use, Degron also apply phenotypic screen and top-down proteomic to identifying more novel targets.
ROBUST PIPELINE OF NOVEL TARGETS
Degron's technology platform allows for discovering and validating many new disease targets, most of which are undruggable targets not discovered by other MGD companies.
了解更多 NEWS
NEWS
December 18, 2023
Degron Therapeutics won the 2023 BRACE Award Venture Competition along with the investment...
Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition after thr
October 18, 2023
Degron Therapeutics Wins the Second Prize in 2023 Women’s Venture Competition, the First A...
Degron Therapeutics and its Co-founder and CEO, Lily Zou, Ph.D., MBA won the Second Prize in 2023 Wo
Feb. 7, 2023
Dr. Xiaobing Qian joins Degron Therapeutics as Chief Development Officer
Shanghai, China and San Diego, CA, February 7, 2023, Degron Therapeutics Inc. announced today that X
Contact us